

Attorney Docket No: 23546-07724US  
Client Ref: RTS-0333  
USSN: 10/008,789

### AMENDMENTS TO THE CLAIMS

1. (currently amended): A compound 8 to 50 nucleobases in length targeted to the 5'-untranslated region, the start codon region, the coding region, the stop codon region, or the 3'-untranslated region of a nucleic acid molecule of SEO ID NO:3 encoding thyroid hormone receptor interactor 6, with the proviso of not including nucleobases 1608 through 1642 of SEO ID NO:3, wherein said compound specifically hybridizes with one of said regions and inhibits the expression of thyroid hormone receptor interactor 6.
2. (original): The compound of claim 1 which is an antisense oligonucleotide.
3. (previously canceled)
4. (original): The compound of claim 2, wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage.
5. (original): The compound of claim 4, wherein the modified internucleoside linkage is a phosphorothioate linkage.
6. (original): The compound of claim 2, wherein the antisense oligonucleotide comprises at least one modified sugar moiety.
7. (original): The compound of claim 6, wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety.
8. (original): The compound of claim 2, wherein the antisense oligonucleotide comprises at least one modified nucleobase.
9. (original): The compound of claim 8, wherein the modified nucleobase is a 5-methylcytosine.
10. (original): The compound of claim 2, wherein the antisense oligonucleotide is a chimeric oligonucleotide.
11. (canceled)
12. (original): A composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier or diluent.

Attorney Docket No: 23546-07724US  
Client Ref: RTS-0333  
USSN: 10/008,789

13. (original): The composition of claim 12 further comprising a colloidal dispersion system.

14. (original): The composition of claim 12, wherein the compound is an antisense oligonucleotide.

15. (previously presented): A method of inhibiting the expression of thyroid hormone receptor interactor 6 in cells or tissues comprising contacting said cells or tissues *in vitro* with the antisense compound of claim 1 so that expression of thyroid hormone receptor interactor 6 is inhibited.

16-18. (canceled)

19. (currently amended): The compound of claim 1 targeted to a nucleic acid molecule encoding thyroid hormone receptor interactor 6, wherein said compound specifically hybridizes with and differentially inhibits by at least 41% the expression of one or more of the variants of thyroid hormone receptor interactor 6 relative to the remaining variants of thyroid hormone receptor interactor 6.

20. (previously presented): The compound of claim 19 targeted to a nucleic acid molecule encoding thyroid hormone receptor interactor 6, wherein said compound hybridizes with and specifically inhibits the expression of TRIP6-I (SEQ ID NO:3).

21. (withdrawn): The compound of claim 2 wherein the antisense oligonucleotide has a sequence comprising SEQ ID NO: 13, 14, 16, 17, 18, 19, 22, 23, 25, 26, 27, 29, 30, 31, 33, 35, 40, 41, 43, 45, 46, 47, 48, 49, 51, 53, 54, 55, 56, 57, 59, 60, 61, 64, 65, 66, 67, 68, 69, 70, 71, 72, 74, 76, 78, 81, 84, 87 or 88.

22. (withdrawn): The compound of claim 21, wherein the antisense oligonucleotide has a sequence comprising SEQ ID NO:22.